介绍一种基于微生物组的新型个性化治疗炎症性肠病:来自NostraBiome内部验证研究的结果
Adrian Goldiș1, Radu Dragomir2, Marina Adriana Mercioni3,4
1Department of Gastroenterology and Hepatology, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Biomedicines
|April 29, 2025
概括
个性化微生物组调制 (PMM) 显著改善了炎症性肠病 (IBD) 患者的症状并减少了炎症. 这种人工智能驱动的方法为IBD管理提供了一个有前途的辅助疗法.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD),包括性结肠炎和克罗恩病,涉及慢性肠道炎症,微生物失生症和免疫功能障碍.
- 目前的IBD疗法往往显示出有限的疗效或随着时间的推移效果的丧失.
- 需要新的治疗策略来有效管理IBD.
研究的目的:
- 评估个性化微生物组调制 (PMM) 在中度至重度IBD患者的临床疗效.
- 评估PMM对症状控制,缓解率和炎症标志物的影响.
- 确定PMM是否可以改善IBD患者的营养状况和生活质量.
主要方法:
- 一个单臂的开放标签试验,涉及27名IBD患者,之前的治疗失败.
- 三个月的PMM干预包括基于微生物组测序的个性化饮食,益生菌和抗菌剂.
- 主要结局:便频率/一致性,C反应蛋白 (CRP),便中的calprotectin. 二次结果:营养状况,代谢功能,生活质量.
主要成果:
- 大量减少便频率 (58%) 和改善便的一致性.
- 显著降低CRP和便calprotectin,表明炎症减少.
- 改善营养缺乏 (铁,B12,D),体重增加和能量水平.
结论:
- 个性化微生物组调制 (PMM) 对IBD患者具有显著的临床,炎症和代谢益处.
- PMM显示出作为辅助疗法的潜力,可能与抗TNF生物药物产生协同作用.
- 需要进行更大规模的试验来确认长期疗效和更广泛的适用性.
关键词:
人工智能驱动的治疗方法生物疗法是一种生物疗法.便中的calprotectin是一种便的calprotectin.肠道失调症是一种肠道失调症.炎症性肠病是一种炎症性肠病.炎症标志物的炎症标志物微生物组是一个微生物组.个性化医疗是个性化的医疗.益生菌是一种益生菌.更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
253
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
253
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
108
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
108
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
Drugs for Treatment of Ulcerative Colitis in IBD
109
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
109


